Results 1 to 10 of about 26,257 (175)

Provirus Mutations of Human T-Lymphotropic Virus 1 and 2 (HTLV-1 and HTLV-2) in HIV-1-Coinfected Individuals [PDF]

open access: yesmSphere, 2020
Provirus mutations of human T-lymphotropic virus 1 (HTLV-1), mostly the lack of the 5′ long terminal repeat (LTR) genomic region, have been described and associated with severe adult T cell leukemia/lymphoma (ATLL), non-sense point mutations with low ...
Karoline Rodrigues Campos   +1 more
doaj   +2 more sources

Prevalence of human T-lymphotropic virus 1/2 in Nigeria’s capital territory and meta-analysis of Nigerian studies [PDF]

open access: yesSAGE Open Medicine, 2019
Objectives: This study was aimed at determining human T-lymphotropic virus 1/2 prevalence among apparently healthy, immunocompromised and haematologic malignant individuals in Nigeria’s capital, as well as meta-analysis of all Nigerian studies until date.
Nneoma Confidence JeanStephanie Anyanwu   +5 more
doaj   +2 more sources

Epitope-based universal vaccine for Human T-lymphotropic virus-1 (HTLV-1). [PDF]

open access: yesPLoS ONE, 2021
Human T-cell leukemia virus type 1 (HTLV-1) was the first oncogenic human retrovirus identified in humans which infects at least 10-15 million people worldwide. Large HTLV-1 endemic areas exist in Southern Japan, the Caribbean, Central and South America,
Md Thosif Raza   +4 more
doaj   +2 more sources

Human T-Lymphotropic Virus-1–Associated Myelopathy/Tropical Spastic Paraparesis Is Associated With Sexual Dysfunction in Infected Women of Reproductive Age [PDF]

open access: yesSexual Medicine, 2018
Introduction: Human T-lymphotropic virus (HTLV)-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurological disorder that mostly affects women.
Adenilda Lima Lopes Martins, MD, PhD   +6 more
doaj   +2 more sources

COVID‐19 in a human T‐cell lymphotropic virus type‐1 carrier

open access: yesClinical Case Reports, 2022
This is the first report of COVID‐19 in a human T‐cell lymphotropic virus type‐1 (HTLV‐1) carrier. HTLV‐1 infection can cause immune dysfunction even in asymptomatic carriers.
Takatoshi Enomoto   +17 more
doaj   +2 more sources

Concluding Remarks for Special Issue HTLV-HIV Co-Infections

open access: yesViruses, 2023
During the early 1980s, the first 3 human retroviruses were identified: human T-lymphotropic virus 1 and 2 (HTLV-1 and HTLV-2) and human immunodeficiency virus (HIV) [...]
Alejandro Vallejo   +1 more
doaj   +1 more source

Comparative performances of serologic and molecular assays for detecting human T lymphotropic virus type 1 and type 2 (HTLV-1 and HTLV-2) in patients infected with human immunodeficiency virus type 1 (HIV-1)

open access: yesBrazilian Journal of Infectious Diseases, 2017
The present study evaluated several techniques currently available (commercial kits and in-house assays) for diagnosing human T lymphotropic viruses types 1 and 2 in two groups of patients enrolled at HIV/AIDS specialized care services in São Paulo ...
Karoline Rodrigues Campos   +3 more
doaj   +1 more source

Organizing pneumonia in a carrier of human T-cell lymphotropic virus type-1

open access: yesAnnals of Thoracic Medicine, 2020
Human T-cell lymphotropic virus type-1 (HTLV-1)-associated bronchioloalveolar disorders (HABAs) are pulmonary disorders with various interstitial lung disease patterns that often occur in HTLV-1 carriers.
Masahiro Yamasaki   +3 more
doaj   +1 more source

Pain prevalence, characteristics and associated factors in human T-cell lymphotropic virus type 1 infected patients: a systematic review of the literature

open access: yesBrazilian Journal of Infectious Diseases, 2016
Objective: To describe the pain in patients infected with human T-cell lymphotropic virus type 1, clinically and epidemiologically. Methods: This systematic review was based on The PRISMA Statement.
Daniel Lordelo San-Martin   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy